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Abstract
Introduction: The metabolic deregulation associated with diabetes mellitus (DM) causes secondary
pathophysiologic changes in multiple organ systems. Endothelial injury is induced by oxidative stress (OS)
and inflammation. We have previously shown that DM type 2 patients are exposed to increased OS and
inflammation contributed in part by primed peripheral polymorphonuclear leukocytes (PMNLs).
Aims: To characterize the effect of oral medication on PMNL priming, on PMNL-related and on systemic
inflammation, in correlation to changed diabetes parameters in patient with newly diagnosed type 2 DM.
Methods: PMNLs were separated from DM patient's prior and following treatment with either metformin
(Glucophage), or Thiazolidinedione (rosiglitazone) and from healthy control subjects (HC). Rate of
superoxide release from phorbol ester-stimulated PMNLs and CD11b on PMNLs assessed PMNL priming.
White blood cells (WBC) and PMNL counts and apoptosis reflected PMNL-related inflammation. CRP,
fibrinogen, transferrin and albumin blood levels reflected systemic inflammation.
Results: Both metformin and rosiglitazone treatments reduced significantly the high levels of glucose and
HbA1c, and slightly improved lipid profile during 2 months. PMNL priming parameters, higher compared
to HC, increased after 2 months of metformin treatment. Rosiglitazone treatment decreased PMNL
priming. ALP, higher in DM, significantly decreased following 2 months of both treatments. Systemic
inflammation markers (fibrinogen, CRP), higher in DM, decreased following both treatments. Transferrin
and albumin were similar to HC. PMNL-related inflammation markers were higher in DM; however, only
PMNL apoptosis decreased after both treatments. Monocyte counts, higher in DM compared to HC,
decreased following both treatments. Serum insulin levels, higher in DM compared to HC, decreased
following both treatments. PMNL-related priming and inflammation parameters positively correlated with
HbA1c.
Conclusion: The present research adds new facet in evaluating anti-hyperglycemic treatment in type 2
DM patients. Despite sufficient glycemic control using both treatments, some PMNL-related parameters
deteriorated. Thus, anti hyperglycemic treatment should be favored due to its combined anti-PMNL
priming and anti-inflammatory effect, in addition to its anti-hyperglycemic characteristics, according to the
correlation among these parameters. Such combined treatment may reduce morbidity and mortality
common in DM patients.
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Background
Atherosclerosis begins during adolescence in otherwise
healthy individuals; it develops earlier in type 2 diabetic
patients and frequently is the leading cause of premature
mortality. Whereas there is now highly persuasive evi-
dence that glycemic control reduces the the risk of micro-
vascular complications in type 1 diabetes, and probabily
in type 2 diabetes as well, such evidence is unavailable for
macrovascular complications. There is a close linkage bet-
tween rapidly developing atherosclerosis in diabetic
patients and endothelial dysfunction and insulin resist-
ance in diabetes mellitus [1-3]. Endothelial dysfunction
appears to predate the development of diabetic angiopa-
thy and play a key role in the pathogenesis of diabetic
angiopathy in man. Insulin resistance, oxidative stress,
and inflammation all play a key role and participate in the
development of endothelial dysfunction [4-7]. Much evi-
dence support the presence of insulin resistance as the
fundamental pathophysiologic disturbance for the
clauster of metabolic and cardiovascular disorders, known
as the metabolic syndrome. Oxidative stress is believed to
play a role in diabetic-induced vascular complication [8-
10]. Chronic exposure to increased levels of hydroxyl rad-
icals in vivo likely plays a significant role in the origine of
diabetes-associated endothelial dysfunction. Diabetic
endothelium produce increase in both superoxide anion
radicals and hydrogen peroxide leading to enhanced
intracellular production of hydroxyl radicals that could be
implicated in diabetes-induced endothelial dysfunction.
Chronic treatment with a known hydroxyl radical scaven-
ger, dimethylthiourea, could prevent endothelial dysfunc-
tion in diabetes. Other indicators for the oxidative stress
in diabetes the elevated levels of advanced glycation end
products (AGE) that rise in parallel with the severity and
complications of the disease [11,12], as we can demon-
strate this during the elevation of HbA1c in diabetes [13].
We have previously shown that in other clinical situations
known to be associated with endothelial dysfunction and
accelerated atherosclerosis such as uremia, hypertension
and type 2 diabetes, PMN are primed, contributing to OS
and inflammation [14-16]. PMNLs from diabetic patients
demonstrated defects in LPS-induced apoptosis. High-
glucose environment may mediate these findings. The
inability of diabetic neutrophils to reduce apoptosis fol-
lowing LPS exposure resulted in relatively increased apop-
tosis. This would cause decreased functional longevity of
neutrophils and increased neutrophil clearance from
infectious sites, possibly contributing to the increased sus-
ceptibility and severity of infections in diabetic patients
[17]. Other inflammatory markers found in diabetes as
elevated levels of sCD14 [18], fibrinogen and CRP that
shown a significant correlation with PMNLs [19,20].
Monocytes are the principal inflammatory cells associated
with the plaque formation, adherence of monocytes to the
arterial wall is an early event in the development of
atherosclerotic lesions. In uncontrolled diabetes with ele-
vated HbA1c as in hyperglycemia in vitro, the peripheral
blood monocytes are preferentially recruited to the intima
early in the development of atheroma, they adhere to
endothelium, migrate to the subendothelial space, and
trasformed into lipid-lader foamy macrophages [21-25].
High doses of vitamin E (800 IU/day) can decrease the
recruitment of monocytes to endothelim and cause decre-
ment in oxidized LDL and the level of various plasma
interleukines [22,24]. Therefore any drug that can
decrease the activation of PMNLs or the monocytes, oxi-
dative stress and inflammation should be preferable and
better than drugs that treat only the hyperglycemia. Thus,
in the present study we compare PMNL priming parame-
ters in diabetic patients, treated daily with metformin for
two months to those treated with rosiglitazone.
Research design and methods
Study population
Thirty untreated DM patients patients were included in
this study: All the participants in this study were in age
range of 30–65 year and nonsmokers. Patients underwent
medical evaluation including opthalmoscopic examina-
tion, ECG and laboratory tests. The following exclusion
criteria that were applied for the diabetic patients: signifi-
cant dyslipidemia – LDL-cholesterol ≥ 130 mg%, HDL-
cholesterol ≤ 35 mg%, triglycerides ≥ 400 mg%; evidence
for microvascular diseases (diabetic retinopathy and dia-
betic nephropathy) and evidence for macrovascular dis-
ease (coronary artery disease, cerebrovascular disease and
peripheral vascular disease); obese, BMI ≥ 30; Blood pres-
sure > 130/85.
The untreated DM patients were further enrolled in a pro-
spective longitudinal study, being followed up for 4 and 8
weeks of either metformin (850 mg/day) or rosiglitazone
(4 mg/day) treatment.
A group of age- and gender-matched healthy controls
(HC, n = 20) were included in the study. The inclusion of
HC participants was based upon a clinical examination
with laboratory confirmation. Patients and subjects gave
informed consent for blood sampling approved by the
institutional committee in accordance with the Helsinki
declaration.
PMNL and sera separation
Blood was drawn in the morning after an overnight fast
from hyperlipidemic patients and HC for the determina-
tion of biochemical and hematological parameters and
for PMNL isolation. PMNL isolation was carried out from
a 20 mL heparinized blood sample as previously
described [15,16,26]. The separated PMNLs (>98% pure,
approximately 107 cells per isolation) were resuspended
in phosphate buffered saline (PBS) containing 0.1% glu-Cardiovascular Diabetology 2008, 7:20 http://www.cardiab.com/content/7/1/20
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cose. Sera were used for the determination of C-reactive
protein (CRP), albumin and transferrin while plasma
served for fibrinogen quantification.
PMNL priming
a. Rate of superoxide release
The measurements of the rate of superoxide release are
based on superoxide dismutase (SOD) inhibitable reduc-
tion of 80 μM cytochrome C (Sigma, St. Louis, MO., USA)
to its ferrous form. The rate of superoxide release was
monitored from 106 separated PMNLs at 22°C up to 90
min as previously described [15,16,27].
b. Membrane CD11b
The PMNL membrane adhesion molecule CD11b was
determined by flow cytometry, reflecting PMNL priming
[28]. Whole blood was treated with 0.1% formic acid to
lyse the erythrocytes, and mouse anti human-CD11b phy-
coreythrin (PE)-conjugated antibody (Immunotech, Mar-
seille, France) was added. Anti-human CD16 PC5-
conjugated antibody (Immunotech, Marseille, France)
was also used in all samples to enable gating on the PMNL
population.
PMNL-derived inflammation
a. WBC, PMNL and monocyte counts
Counts of WBC, PMNLs and monocytes from blood
drawn in EDTA were performed by an automated cell
counter (Coulter STKS, Miami, Fla., USA).
b. Analysis of apoptotic PMNLs
Apoptosis was determined in whole blood from 20 ran-
domly chosen hyperlipidemic patients and 20 HC by flow
cytometry according to Kuypers et al. [29]. Briefly,
Annexin V kit (Bender MedSystems, Vienna, Austria) was
applied to blood samples after lysis of red blood cells by
Q prep (Beckman Coulter, Fullerton, California, USA).
Monoclonal anti-CD16 labeled with PC5, was used for
gating on PMNLs.
Systemic inflammation
a. Positive acute phase protein
Fibrinogen and CRP
Fibrinogen levels were measured in plasma using the K-
Assay® kit (Kamiya Biomedical Company) by chemical
analyzer (Cobas Mira, Roche Diagnostics, Germany).
Blood CRP levels were measured using commercial kit
(Biokit, Spain) by the Hitachi 917 Automatic analyzer
(Roche Diagnostics, Germany).
b. Negative acute phase proteins
Albumin and transferrin
Blood albumin (Alb plus, Roche Diagnostics, Manheim,
Germany) and transferrin (Transferrin ver.2, Roche Diag-
nostics, Manheim, Germany) levels were measured using
the Hitachi 917 Automatic analyzer (Roche Diagnostics,
Germany).
Statistical Analysis
Data values are means ± SD. The two groups were com-
pared by student t-test, using Prism version 3.0 statistical
software (GraphPad software, San Diego, Ca). Correla-
tions between different study parameters were performed
using Pearson correlation coefficients. P < 0.05 was con-
sidered significant.
Results
Study population
Table 1 summarizes the biochemical characteristics of the
participants. All studied groups of patients showed similar
age range, blood pressure values, serum cholesterol,
serum triglycerides, and liver enzymes, without showing
target organ damage. Most traditional risk factors were
similar during antihyperglycemic treatment period. ALP
was higher in DM compared to HC and decreased during
2 months of both treatments (Table 1). Along with its role
as an hepatic enzyme, former studies have shown signifi-
cantly higher blood level of this enzyme in hypertensive
patients and rats, following degranulation from primed
PMNLs [14]. The present study adds DM patients to this
finding, and shows ameliorating results following both
antihyperglycemic treatment.
The diabetes characteristics over 8 weeks period of antihy-
perglycemic treatment is depicted in Table 1: Blood
HbA1c and glucose levels significantly decreased follow-
ing both treatment. Insulin levels, significantly higher in
DM compared to HC, decreased following both antihy-
perglycemic treatment (Table 1).
Effect of metformin and rosiglitazone on diabetes 
characteristics and PMNL priming-related parameters
PMNL priming parameters revealed different picture with
each antihyperglycemic treatment; the metformin-treated
patients showed significant increase in PMNL priming, as
reflected by significant increase either in the rate of super-
oxide release from separated PMNLs or in CD11b levels
on PMNLs (Fig. 1a and 1b, respectively). However, the
rosiglitazone treatment inhibited significantly either the
rate of superoxide release from separated PMNLs or in
CD11b levels on PMNLs (Fig. 1a and 1b, respectively). It
has to be emphasized that both groups of patients showed
higher values of PMNL priming compared to those meas-
ured in HC subjects.
PMNL-derived inflammation
a. WBC, PMNL and monocytes counts
Counts of WBC and PMNLs, significantly higher in DM
compared to HC, decreased only after rosiglitazone treat-
ment, while metformin treatment caused a rise in theseCardiovascular Diabetology 2008, 7:20 http://www.cardiab.com/content/7/1/20
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cells' count (Table 2). The significant higher level of
monocytes in DM patients, decreased significantly after
both antihyperglycemic treatments (Table 2).
b. Analysis of apoptotic PMNLs
Apoptosis of PMNLs, higher in DM, decreased signifi-
cantly after both antihyperglycemic treatments (Table 2).
Systemic inflammation
a. Positive acute phase protein
Fibrinogen and CRP levels, higher in DM, decreased sig-
nificantly after both antihyperglycemic treatments (Table
2).
b. Negative acute phase proteins
Albumin and transferrin levels were similar to HC and did
not change following antihyperglycemic treatment (Table
2).
Severity of diabetes and OS
Blood HbA1c but not blood glucose levels were signifi-
cantly positively correlated with the rates of superoxide
release from PMA-stimulated PMNLs separated from all
studied DM patients (R = 0.4, P = 0.004, Figure 2A; R =
0.081, P = 0.52, Figure 2B, respectively). Similar correla-
tion was found with the second parameter of PMNL prim-
ing, namely CD11b (R = 0.4; P = 0.03). Similarly, Blood
HbA1c levels were significantly positively correlated with
WBC (R = 0.4, P = 0.005) or with PMNL counts (R = 0.5,
P  = 0.0008; Figure 3, respectively). These findings are
indicative of relation between OS and the severity the dis-
ease, as reflected by HbA1c levels.
Discussion
Our results show that type 2 diabetic patients are exposed
to oxidative stress and chronic inflammation (partially
because of the primed state of their PMNLs) before any
clinical evidence of angiopathy exist [15]. When sepa-
rated, PMA-stimulated diabetic PMNLs release superoxide
significantly faster than normal control PMNLs and con-
comitantly with a reduced level of the plasma antioxidant
GSH, predisposing these patients to OS [15]. Thirty
untreated DM patients patients were included in this
study: All the participants in this study were in age range
of 30–65 year and nonsmokers. Patients underwent med-
ical evaluation including opthalmoscopic examination,
ECG and laboratory tests. The untreated DM patients were
further enrolled in a prospective longitudinal study, being
followed up for 4 and 8 weeks of either metformin (850
mg/day) or rosiglitazone (4 mg/day) treatment. A group
of age- and gender-matched healthy controls (HC, n = 20)
were included in the study.
Blood HbA1c and glucose levels significantly decreased
following both treatment. Insulin levels, significantly
higher in DM compared to HC, decreased following both
antihyperglycemic treatment. Lipid profile (LDL-C, trig-
lycerides) was also improved after two months following
antihyperglycemic treatment as was described in literature
[25]. PMNL priming parameters revealed different picture
with each antihyperglycemic treatment; the metformin-
treated patients showed significant increase in PMNL
priming, as reflected by significant increase either in the
rate of superoxide release from separated PMNLs or in
CD11b levels on PMNLs. However, the rosiglitazone
Table 1: The changes in DM patients' parameters.
Parameters HC Metformin (months) Rosiglitazone (months)
0120 2
Fundus neg neg neg neg neg neg
MAP (mm Hg) 87.0 ± 2.2 99 ± 3.2 98.1 ± 1.4 99.1 ± 3.6 96.1 ± 2.0 96.2 ± 0.2
Glucose (mg/dL) 94.0 ± 11.9 228.4 ± 15.1b 135.3 ± 8.3a,b 135.9 ± 3.2a,b 235.2 ± 15.8b 143.1 ± 14.1a,b
HbA1c (μmol/L) 5.4 ± 0.2 8.9 ± 0.3b 7.2 ± 0.5a,b 7 ± 0.1a,b 10.7 ± 0.6b 7 ± 0.3a,b
Calculated GFR 94.6 ± 2.9 99.5 ± 2.1 95.7 ± 2.0 94.6 ± 2.9 95.4 ± 4.8 90.1 ± 4.1
Cholesterol (mg/dL) 205.0 ± 1.7 203 ± 8.6 188.3 ± 9.9 188.3 ± 2.2 207.3 ± 9.0 195.1 ± 4.8
Triglycerides (mg/dL) 120.4 ± 3.2 153.2 ± 2.1 114.6 ± 26.3 129.3 ± 6.5 190.2 ± 3.5 141.4 ± 5.5
HDL (mg/dL) 58.6 ± 0.7 45.9 ± 2.5 44.7 ± 3.4 43.9 ± 0.9 42.04 ± 2.4 41.3 ± 0.9
LDL (mg/dL) 114.6 ± 1.3 128.4 ± 7.5 120.7 ± 8.7 118.6 ± 2.1 130.0 ± 7.7 114.7 ± 2.6
Hb (g/dL) 14.3 ± 0.1 14.6 ± 0.4 14.0 ± 0.6 14.8 ± 0.5 14.7 ± 0.3 14.4 ± 0.1
ALT (U/L) 20.3 ± 0.5 27.3 ± 2.8 28.4 ± 5 20.3 ± 0.5 33.5 ± 6.5 24.3 ± 0.7a
AST (U/L) 19.6 ± 0.3 19.2 ± 1.5 24 ± 3.6 19.6 ± 0.3 23 ± 3 17.4 ± 0.3a
ALP (U/L) 76.2 ± 6.1 87.3 ± 4.8b 73.7 ± 3.9a 76.2 ± 6.1a 83.8 ± 4.5b 75.3 ± 1.5a
LDH (U/L) 283.3 ± 1.9 311 ± 17 273.2 ± 10.8 283.3 ± 1.9 270.4 ± 10.8 255.8 ± 3.3
Insulin (μU/mL) 7.6 ± 0.8 15.2 ± 1.4b 13.5 ± 1.0b 11.1 ± 0.9a,b 17.5 ± 1.8b 9.5 ± 0.4a,b
a P < 0.05, treated DM patients vs. untreated DM patients;
b P < 0.05, untreated DM patients vs. HC subjectsCardiovascular Diabetology 2008, 7:20 http://www.cardiab.com/content/7/1/20
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PMNL priming parameters, namely, rate of superoxide release (a) and PMNL CD11b levels (b), before and following 1 and 2  months of either metformin (blank) or combined Roziglytazone (dotted) treatment Figure 1
PMNL priming parameters, namely, rate of superoxide release (a) and PMNL CD11b levels (b), before and following 1 and 2 
months of either metformin (blank) or combined Roziglytazone (dotted) treatment. Data are mean ± SEM. aP < 0.05, vs. HC 
subjects; b P < 0.05, vs. untreated DM patients.
a
b Cardiovascular Diabetology 2008, 7:20 http://www.cardiab.com/content/7/1/20
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treatment inhibited significantly either the rate of super-
oxide release from separated PMNLs or in CD11b levels
on PMNLs. It has to be emphasized that both groups of
patients showed higher values of PMNL priming com-
pared to those measured in HC subjects. ALP was higher
in DM compared to HC and decreased during 2 months
of both treatments. Along with its role as an hepatic
enzyme, former studies have shown significantly higher
blood level of this enzyme in hypertensive patients and
rats, following degranulation from primed PMNLs [14].
Table 2: The changes in DM patients' inflammation parameters.
Parameters HC Metformin (months) Rosiglitazone (months)
01 20 2
WBC × 109 6.7 ± 0.1 7.3 ± 0.3b 7.4 ± 0.4 7.5 ± 0.2 7.04 ± 0.5b 6.8 ± 0.6
PMNLs × 109 4.0 ± 0.1 4.6 ± 0.3b 4.7 ± 0.2 4.9 ± 0.1 4.2 ± 0.4b 4.4 ± 0.5
PMNL apoptosis (%) 4.0 ± 0.1 12.7 ± 3.4b 9.5 ± 2.8a, b 6.5 ± 1.0a 20.4 ± 4.4b 7.5 ± 1.9a
Monocytes × 109 0.36 ± 0.02 0.44 ± 0.05b 0.40 ± 0.04b 0.39 ± 0.04a 0.49 ± 0.03b 0.39 ± 0.01a
Fibrinogen (mg/dl) 304.6 ± 17.6 440.1 ± 25.2b 471.1 ± 28.8b 415.9 ± 41.2a, b 400 ± 16.6b 332.8 ± 8.1a,b
Albumin (g/dl) 4.6 ± 0.05 4.53 ± 0.1 4.74 ± 0.1 4.7 ± 0.04 4.5 ± 0.1 4.6 ± 0.1
Transferrin (g/dl) 273.2 ± 10.6 274.6 ± 8.4 276.7 ± 7.2 287.9 ± 7.7 264.7 ± 7.6 286.2 ± 8.9
CRP (mg/L) 1.5 ± 0.1 8.3 ± 1.6b 6.6 ± 1.1b 5.8 ± 1.5a, b 4.3 ± 0.9b 1.8 ± 0.2a,b
a P < 0.05, treated DM patients vs. untreated DM patients;
b P < 0.05, untreated DM patients vs. HC subjects
Correlation between the rates of superoxide release from  separated PMA-stimulated PMNLs and either blood HbA1c  (A) or blood glucose levels (B) Figure 2
Correlation between the rates of superoxide release from 
separated PMA-stimulated PMNLs and either blood HbA1c 
(A) or blood glucose levels (B). Data refers to values from 
DM patients and HC subjects.
Correlation between blood HbA1c levels and either (A)  WBC or PMNL (B) counts Figure 3
Correlation between blood HbA1c levels and either (A) 
WBC or PMNL (B) counts. Data refers to values from DM 
patients and HC subjects.Cardiovascular Diabetology 2008, 7:20 http://www.cardiab.com/content/7/1/20
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The present study adds DM patients to this finding, and
shows ameliorating results following both antihyperglyc-
emic treatment. Counts of WBC and PMNLs, significantly
higher in DM compared to HC, decreased only after ros-
iglitazone treatment, while metformin treatment caused a
rise in these cells' count. The significant higher level of
monocytes in DM patients, decreased significantly after
both antihyperglycemic treatments. Albumin and trans-
ferrin levels were similar to HC and did not change fol-
lowing antihyperglycemic treatment. Other inflammatory
markers like fibrinogen and CRP levels, higher in DM,
decreased significantly after both antihyperglycemic treat-
ments. Apoptosis of PMNLs, higher in DM, decreased sig-
nificantly after both antihyperglycemic treatments. Blood
HbA1c but not blood glucose levels were significantly
positively correlated with the rates of superoxide release
from PMA-stimulated PMNLs separated from all studied
DM patients (R = 0.4, P = 0.004, R = 0.081, P = 0.52,
respectively). Similar correlation was found with the sec-
ond parameter of PMNL priming, namely CD11b (R =
0.4; P = 0.03). Similarly, Blood HbA1c levels were signifi-
cantly positively correlated with WBC (R = 0.4, P = 0.005)
or with PMNL counts (R = 0.5, P = 0.0008; respectively).
These findings are indicative of relation between OS and
the severity of the disease, as reflected by HbA1c levels.
Likewise, multiple clinical trials show that reduction of
HbA1c and blood glucose with the known antihyperglyc-
emic treatments was optimal but all other inflammatory
markers were worsen during the same treatment [21-26].
There is a great disagreement if tight control of glycaemia
and decreasing HbA1c is sufficient to prevent the danger
and risk for cardiovascular diseases and atherosclerosis.
Conclusion
Our present research adds new facet in evaluating anti-
hyperglycemic treatment in type 2 DM patients. Despite
sufficient glycemic control achieved using both treat-
ments, some PMNL-related parameters deteriorated.
Thus, anti hyperglycemic treatment should be favored due
to its combined anti-PMNL priming and anti-inflamma-
tory effect, in addition to its anti-hyperglycemic character-
istics, according to the correlation among these
parameters. Such combined treatment may reduce mor-
bidity and mortality common in DM patients [30,31].
Multiple other studies showed the beneficial effects of
Thiazolidinediones (rosiglitazone) on cardiovascular dis-
ease in diabetes beyond improving blood glucose control
[32-36]. There is a great need to complete this research
with more time periods and sample to check the relation
between the OS index and other inflammatory markers
and the various anti hyperglycemic treatments in the
reduction of mortality and morbidity.
Abbreviations
DM: Diabetes mellitus; HbA1c: glycosylated hemoglobin
A; HC: healthy control subjects; OS: oxidative stress; PMA:
phorbol 12-myristate 13-acetate; PMNLs: polymorphonu-
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superoxide dismutase.
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